Due to Xmas holidays, our last days of shipping will be as follow: International Dec 18, 2020. USA: Dec 21, 2020. The shipments will resume as usual on International: Jan 8, 2021 and USA: Jan 4, 2021.
KIF5B-RET (V804L), Active (R02-19HG)

KIF5B-RET (V804L), Active (R02-19HG)

  • $259.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :Recombinant human fusion KIF5B (1- 575 a.a., exons1-15) –RET (V804L) (713 a.a. – end, exons 14-21), was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.

Species :Human

Tag :GST

Expression System:Sf9 insect cells using baculovirus

Sequence :1- 575 a.a., exons1-15 (KIF5B) – 713 a.a. – end, exons 14-21 (RET (V804L))

Genbank Number :NM_004521
NM_020630

Specific Activity :Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.

Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.

Storage, Stability and Shipping :Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Molecular Weight :132 kDa

Gene Aliases :KIF5B: KINH, UKHC, KNS
RET: CDHF12, RET51, PTC, RET-ELE1; RET/PTC2

Scientific Background :RET or ret proto-oncogene is a member of the cadherin superfamily that encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. RET can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement (1). RET signaling pathway, by regulating the development of both the nervous and lymphoid system in the gut, plays a key role in the molecular mechanisms that orchestrate intestine organogenesis (2). The KIF5B-RET fusion was reported to be one of the driver mutations of lung adenocarcinomas and that Vandetanib inhibits the anchorage-independent growth activity induced by the fusion.

References :
1. Grieco, M. et.al: PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60: 557-563, 1990.

2. Veiga-Fernandes, H. et.al: Tyrosine kinase receptors RET is a key regulator of Peyer's patch organogenesis. Nature 446: 547-551, 2007.

3. Kohno T, et al. : KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012 Feb 12;18(3):375-7.

Product Sheets (By Lot #) :

W3112-1.pdf
E3260-6.pdf

Research Areas :Cancer